Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Real-World Outcomes with Bortezomib-Containing Regimens and Lenalidomide Plus Dexamethasone for the Treatment of Transplant Ineligible MM Patients: A Multi-Institutional Report from the National Myeloma Canada Research Network (MCRN) Database

Victor Jimenez-Zepeda, MD, Donna E Reece, MD, McCurdy R Arleigh, MD MHA, FRCPC, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Michael Sebag, MD PhD, Julie Stakiw, MD FRCPC, Kevin Song, MD, Richard Leblanc, MDFRCPC, Tony Reiman, MD, Martha L Louzada, MD, Rami Kotb, MD, Engin Gul, BSc, Christopher P. Venner, MD FRCPC

Blood (2018) 132 (Supplement 1): 2008.

https://doi.org/10.1182/blood-2018-99-117363

Published: 2018

Journal Articles

MCRN ¯ 003/MYX · 1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies

Christopher P. Venner, MD FRCPC, Richard Leblanc, MDFRCPC, Irwindeep Sandhu, MDFRCPC, Darrell J. White, MD, Andrew R Belch, MD, Donna E Reece, MD, Christine I Chen, MD, Sean Dolan, MD, Andrea Kew, MDFRCP(C), Marc Lalancette, MD FRCP, Martha L Louzada, MD, Arleigh McCurdy, MD BSc, Gail T. McDonald, Tony Reiman, MD, Laura Rodriguez, Lois E. Shepherd, Engin Gul, BSc, Bingshu E. Chen, Annette E Hay

Blood (2018) 132 (Supplement 1): 1984.

https://doi.org/10.1182/blood-2018-99-117824

Published: 2018

Journal Articles

Targeted-Capture Sequencing Approach to V(D)J Rearrangement, Immunoglobulin (Ig) Translocation and Mutation Detection in Multiple Myeloma (MM): Potential Applications in Minimal Residual Disease (MRD) Analysis and Comparison to Multiparameter Flow Cytometry (MFC) in the Myeloma Canada Research Network (MCRN) 001 Study with Intravenous Busulfan and Melphalan (BuMel) Conditioning Followed By Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM)

Blood (2017) 130 (Supplement 1): 3057.

https://doi.org/10.1182/blood.V130.Suppl_1.3057.3057

Published: 2017

Journal Articles

Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain (HLC) Ratio Assessments

Donna Reece, MD, Giovanni Piza Rodriguez, MD, Mariela Pantoja, PhD MSc, Darrell White, MD, Christopher P. Venner, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin W. Song, MD, Jean Roy, MD, Martha L Louzada, MD, Arleigh McCurdy, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Christine Chen, MD, Harminder Paul, BSc

Blood (2016) 128 (22): 4632.

https://doi.org/10.1182/blood.V128.22.4632.4632

Published: 2016

Journal Articles

Long Term Monitoring of Patients with Positive Lupus Anticoagulant and Antiphospholipid Antibodies. Are All Cases Persistently Positive?

Matthew R. Kovacs, Alejandro Lazo-Langner, MD MSc, FRCPC, Martha L Louzada, MD, Michael J. Kovacs, MD FRCPC

Blood (2016) 128 (22): 1452.

https://doi.org/10.1182/blood.V128.22.1452.1452

Published: 2016

Journal Articles

Lupus Anticoagulant Testing in Patients Receiving Rivaroxaban or Apixaban for the Treatment of Venous Thromboembolism

Matthew R. Kovacs, Alejandro Lazo-Langner, MD MSc, FRCPC, Martha L Louzada, MD, Michael J. Kovacs, MD FRCPC

Blood (2016) 128 (22): 5017.

https://doi.org/10.1182/blood.V128.22.5017.5017

Published: 2016

Journal Articles

A Pilot Study in Cancer Patients with Central Venous Catheter Associated Deep Vein Thrombosis in Upper Extremity Treated with Rivaroxaban (Catheter 2)

Gwynivere A Davies, MD FRCPC, Alejandro Lazo-Langner, MD MSc, FRCPC, Esteban Gandara, MD MSc, FRCPC, Vicky Tagalakis, MD MSc, Martha L Louzada, MD, Roweena Corpuz, RN, Michael J. Kovacs, MD FRCPC

Blood (2016) 128 (22): 878.

https://doi.org/10.1182/blood.V128.22.878.878

Published: 2016

Journal Articles

Safety of Weight-Adjusted Dosing of LMWH in Clinically Obese Cancer Patients with Venous Thromboembolism

Gillian Mount, MD MSc, Michael J. Kovacs, MD FRCPC, Alejandro Lazo-Langner, MD MSc, FRCPC, Lenicio Siqueira, BSc, Martha L Louzada, MD

Blood (2016) 128 (22): 882.

https://doi.org/10.1182/blood.V128.22.882.882

Published: 2016

NARROW

Real-World Outcomes with Bortezomib-Containing Regimens and Lenalidomide Plus Dexamethasone for the Treatment of Transplant Ineligible MM Patients: A Multi-Institutional Report from the National Myeloma Canada Research Network (MCRN) Database

MCRN ¯ 003/MYX · 1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies

Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain (HLC) Ratio Assessments

Long Term Monitoring of Patients with Positive Lupus Anticoagulant and Antiphospholipid Antibodies. Are All Cases Persistently Positive?

Lupus Anticoagulant Testing in Patients Receiving Rivaroxaban or Apixaban for the Treatment of Venous Thromboembolism

A Pilot Study in Cancer Patients with Central Venous Catheter Associated Deep Vein Thrombosis in Upper Extremity Treated with Rivaroxaban (Catheter 2)

Safety of Weight-Adjusted Dosing of LMWH in Clinically Obese Cancer Patients with Venous Thromboembolism

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only